SUCCESSFUL LONG-TERM REMISSION IN AGGRESSIVE YOUNG-ONSET CHRONIC LYMPHOCYTIC LEUKEMIA WITH IBRUTINIB AND VENETOCLAX: A DECADE-LONG CASE STUDY
Chronic Lymphocytic Leukemia (CLL) typically affects older individuals and is frequently associated with genetic mutations that help predict its progression. However, this report presents a rare case of aggressive CLL in a young woman with no unfavorable genetic markers, who achieved lasting remissi...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-12-01
|
| Series: | Hematology, Transfusion and Cell Therapy |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2531137924028670 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850119899242823680 |
|---|---|
| author | Naciye Nur Tozluklu Birol Guvenc |
| author_facet | Naciye Nur Tozluklu Birol Guvenc |
| author_sort | Naciye Nur Tozluklu |
| collection | DOAJ |
| description | Chronic Lymphocytic Leukemia (CLL) typically affects older individuals and is frequently associated with genetic mutations that help predict its progression. However, this report presents a rare case of aggressive CLL in a young woman with no unfavorable genetic markers, who achieved lasting remission following the use of dual targeted therapy, after standard treatments repeatedly failed.A 40-year-old woman was diagnosed with CLL during a routine blood examination. Despite lacking any high-risk genetic indicators, her disease advanced swiftly over the next ten years. Initial treatment with CVP (cyclophosphamide, vincristine, prednisone) provided only a brief partial remission. A subsequent course of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) also led to relapse within a few months.Ibrutinib was introduced as a single-agent treatment but failed to control the disease. The patient's condition continued to deteriorate, with recurring lymph node enlargement and rising lymphocyte counts. Three years ago, venetoclax was added to her treatment alongside ibrutinib. This combination therapy produced an extraordinary result—complete remission was achieved, blood counts normalized, lymphadenopathy disappeared, and bone marrow tests showed no trace of residual disease. |
| format | Article |
| id | doaj-art-ebe413ed55904009944c631313beadb3 |
| institution | OA Journals |
| issn | 2531-1379 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Hematology, Transfusion and Cell Therapy |
| spelling | doaj-art-ebe413ed55904009944c631313beadb32025-08-20T02:35:32ZengElsevierHematology, Transfusion and Cell Therapy2531-13792024-12-0146S4010.1016/j.htct.2024.11.024SUCCESSFUL LONG-TERM REMISSION IN AGGRESSIVE YOUNG-ONSET CHRONIC LYMPHOCYTIC LEUKEMIA WITH IBRUTINIB AND VENETOCLAX: A DECADE-LONG CASE STUDYNaciye Nur Tozluklu0Birol Guvenc1Cukurova University Medical Faculty Hospital, Department of Internal Medicine,; Corresponding author.Cukurova University Medical Faculty Hospital, Department of Internal Medicine, Division of HematologyChronic Lymphocytic Leukemia (CLL) typically affects older individuals and is frequently associated with genetic mutations that help predict its progression. However, this report presents a rare case of aggressive CLL in a young woman with no unfavorable genetic markers, who achieved lasting remission following the use of dual targeted therapy, after standard treatments repeatedly failed.A 40-year-old woman was diagnosed with CLL during a routine blood examination. Despite lacking any high-risk genetic indicators, her disease advanced swiftly over the next ten years. Initial treatment with CVP (cyclophosphamide, vincristine, prednisone) provided only a brief partial remission. A subsequent course of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) also led to relapse within a few months.Ibrutinib was introduced as a single-agent treatment but failed to control the disease. The patient's condition continued to deteriorate, with recurring lymph node enlargement and rising lymphocyte counts. Three years ago, venetoclax was added to her treatment alongside ibrutinib. This combination therapy produced an extraordinary result—complete remission was achieved, blood counts normalized, lymphadenopathy disappeared, and bone marrow tests showed no trace of residual disease.http://www.sciencedirect.com/science/article/pii/S2531137924028670Chronic Lymphocytic LeukemiaEarly-Onset CLLResistant CLLVenetoclaxIbrutinib |
| spellingShingle | Naciye Nur Tozluklu Birol Guvenc SUCCESSFUL LONG-TERM REMISSION IN AGGRESSIVE YOUNG-ONSET CHRONIC LYMPHOCYTIC LEUKEMIA WITH IBRUTINIB AND VENETOCLAX: A DECADE-LONG CASE STUDY Hematology, Transfusion and Cell Therapy Chronic Lymphocytic Leukemia Early-Onset CLL Resistant CLL Venetoclax Ibrutinib |
| title | SUCCESSFUL LONG-TERM REMISSION IN AGGRESSIVE YOUNG-ONSET CHRONIC LYMPHOCYTIC LEUKEMIA WITH IBRUTINIB AND VENETOCLAX: A DECADE-LONG CASE STUDY |
| title_full | SUCCESSFUL LONG-TERM REMISSION IN AGGRESSIVE YOUNG-ONSET CHRONIC LYMPHOCYTIC LEUKEMIA WITH IBRUTINIB AND VENETOCLAX: A DECADE-LONG CASE STUDY |
| title_fullStr | SUCCESSFUL LONG-TERM REMISSION IN AGGRESSIVE YOUNG-ONSET CHRONIC LYMPHOCYTIC LEUKEMIA WITH IBRUTINIB AND VENETOCLAX: A DECADE-LONG CASE STUDY |
| title_full_unstemmed | SUCCESSFUL LONG-TERM REMISSION IN AGGRESSIVE YOUNG-ONSET CHRONIC LYMPHOCYTIC LEUKEMIA WITH IBRUTINIB AND VENETOCLAX: A DECADE-LONG CASE STUDY |
| title_short | SUCCESSFUL LONG-TERM REMISSION IN AGGRESSIVE YOUNG-ONSET CHRONIC LYMPHOCYTIC LEUKEMIA WITH IBRUTINIB AND VENETOCLAX: A DECADE-LONG CASE STUDY |
| title_sort | successful long term remission in aggressive young onset chronic lymphocytic leukemia with ibrutinib and venetoclax a decade long case study |
| topic | Chronic Lymphocytic Leukemia Early-Onset CLL Resistant CLL Venetoclax Ibrutinib |
| url | http://www.sciencedirect.com/science/article/pii/S2531137924028670 |
| work_keys_str_mv | AT naciyenurtozluklu successfullongtermremissioninaggressiveyoungonsetchroniclymphocyticleukemiawithibrutinibandvenetoclaxadecadelongcasestudy AT birolguvenc successfullongtermremissioninaggressiveyoungonsetchroniclymphocyticleukemiawithibrutinibandvenetoclaxadecadelongcasestudy |